| 名稱 | CCDC6-RET V804L/BaF3激酶細(xì)胞 |
| 型號(hào) | CBP73215 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | CCDC6-RET V804L/BaF3激酶細(xì)胞 |
產(chǎn)品搜索
相關(guān)文章
- CYP2D6基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- 泛腫瘤大panel質(zhì)控品升級(jí)，免費(fèi)試用申請(qǐng)中
- 分享：CIRCULATE-Japan，輔助治療的“升級(jí)”和“降級(jí)”
- PD-1/L1 &4-1BB雙靶點(diǎn)細(xì)胞篩選模型
- 免疫療法對(duì)一類常見白血病顯療效
- “鉆石突變”ALK基因診斷
- 腫瘤免疫藥靶細(xì)胞模型系列——GITR
- 自身免疫疾病潛力靶點(diǎn)——IL-5藥篩細(xì)胞模型
- EBV分子診斷標(biāo)準(zhǔn)品
- 老靶點(diǎn)迭代突破創(chuàng)新：Her2靶點(diǎn)細(xì)胞模型
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73215CCDC6-RET V804L/BaF3激酶細(xì)胞
- 詳細(xì)內(nèi)容
CCDC6-RET V804L/BaF3激酶細(xì)胞 CBP73215 | |
| I. Introduction | |
Cell Line Name： | CCDC6-RET [V804L]/BaF3 |
Host Cell: | BA/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin |
Mycoplasma Status: | Negative |
| II.Background | |
CCDC6, coiled-coil domain containing 6, has been shown to play a role in the DNA damaging signaling pathway acting as a substrate of ATM (PMID: 17420723). CCDC6 fusions with RET (PMID: 23154560, PMID: 26078337) and BRAF (PMID: 26314551) have been observed in multiple cancer types. | |
| III. Representative Data | |
1.WB of CCDC6-RET V804L/BaF3
| |
2. Sanger of CCDC6-RET [V804L]/BaF3 | |
Figure 2. Breakpoint of CCDC6-RET V804L/BaF3 | |
Figure 3. Point mutation of CCDC6-RET V804L/BaF3 | |
| 3. Anti-proliferation assay | |
Figure 4. Anti-proliferation assay of one reference compounds on the CCDC6-RET V804L/BaF3 Stable Cell Line. | |
會(huì)員_a.png)